Biomolecules and Biomedicine is a pioneering open-access journal dedicated to advancing the fields of molecular biology and biomedical sciences, published by the Association of Basic Medical Science Federation Bosnia & Herzegovina in Sarajevo. With the ISSN 2831-0896 and the E-ISSN 2831-090X, this journal aims to facilitate the dissemination of high-quality research from 2023 onwards, inviting submissions that provide innovative insights and findings across various facets of medicine and biological sciences. Positioned within the General Medicine and Biochemistry, Genetics and Molecular Biology categories, it currently holds rankings of 332 out of 636 and 173 out of 221 respectively, highlighting its emerging influence in these fields. As an open-access journal, it ensures that all published research is freely accessible to a global audience, fostering collaboration and knowledge exchange among researchers, professionals, and students alike. With a commitment to enhancing scientific discourse and promoting cutting-edge research, Biomolecules and Biomedicine is poised to become a vital resource for those dedicated to unraveling the complexities of biomolecules and their roles in health and disease.

JOURNAL OF MOLECULAR MEDICINE (JMM) is a premier publication dedicated to advancing the field of molecular medicine, encompassing critical areas such as drug discovery, genetics, and biochemistry. Published by Springer Heidelberg in Germany, this influential journal has established its significance within the academic community, achieving an impressive Q1 ranking across multiple categories as of 2023, including Drug Discovery, Clinical Genetics, and Molecular Medicine. With a focus on publishing high-quality research and novel insights, JMM appeals to a diverse audience of researchers, professionals, and students passionate about the molecular underpinnings of health and disease. The journal, which has seen a convergence of relevant research spanning from 1976 to 2024, is instrumental in showcasing groundbreaking studies that push the boundaries of knowledge in molecular therapeutics and biomedical science. While it does not offer open access, the rigor of its peer-reviewed content ensures that each publication is a valuable addition to the scientific discourse surrounding molecular medicine. For comprehensive studies and reviews that highlight the intersection of molecular biology and clinical application, look no further than JOURNAL OF MOLECULAR MEDICINE.

FASEB BioAdvances, published by WILEY, is an esteemed open-access journal dedicated to advancing the fields of biochemistry, molecular biology, and physiology. Since its inception in 2019, the journal has rapidly established a significant presence within the academic community, boasting an impressive impact factor reflective of its Q2 and Q3 standings across various categories, including Biochemistry, Genetics and Molecular Biology, Cancer Research, Molecular Medicine, and Physiology. The journal aims to disseminate high-quality research and innovative findings to enhance the understanding of biological processes, making it a vital resource for researchers, professionals, and students alike. With its commitment to open access, FASEB BioAdvances ensures that groundbreaking research is available to a global audience, facilitating collaboration and exploration in these rapidly evolving scientific domains.

Welcome to Immuno, a pioneering open-access journal published by MDPI that serves as a key platform for the dissemination of innovative research in the fields of immunology, biochemistry, and genetics. Established in 2021, this journal has rapidly established itself within the academic community, currently ranking in the 53rd percentile in Medicine (miscellaneous) and 50th percentile in Biochemistry, Genetics, and Molecular Biology according to Scopus metrics. With a commitment to advancing our understanding of immune mechanisms and their applications in health and disease, Immuno is dedicated to publishing high-quality peer-reviewed articles that contribute valuable insights to both researchers and practitioners. Positioned in the heart of Switzerland, its global accessibility and diverse editorial board are a testament to its aim to promote knowledge exchange among scientists, practitioners, and students alike. Explore the latest discoveries and advancements in immunological research through Immuno, where your contributions help shape the future of this critical area of study.

Cancer Communications, published by WILEY, is a leading open-access journal that has positioned itself at the forefront of cancer research and oncology since its inception in 2017. With an impressive HIndex reflective of its scholarly impact and recognized in the Q1 category for both Cancer Research and Oncology as of 2023, this journal consistently ranks in the top echelons of its field, specifically at Rank #16/404 and Rank #13/230 in their respective categories on Scopus. Cancer Communications aims to disseminate cutting-edge research findings, innovative methodologies, and significant advancements in cancer treatments, thereby fostering a deeper understanding of oncology among researchers, healthcare professionals, and students. The journal operates under an Open Access model since 2018, ensuring that vital research is accessible to a global audience, thus enhancing collaboration and knowledge sharing necessary to tackle one of the most pressing health challenges of our time. Located in Hoboken, NJ, United States, and with a strong commitment to scientific excellence, Cancer Communications remains an essential resource for anyone engaged in the fight against cancer.

Cancer Biology & Medicine is a distinguished Open Access journal published by the China Anti-Cancer Association, dedicated to advancing research and understanding in the fields of Cancer Research and Oncology. Since its inception in 2012, the journal has provided a vital platform for the dissemination of high-quality research, evidenced by its impressive ranking within the Q1 and Q2 categories of oncology and cancer research as of 2023. With a significant impact factor and a Scopus ranking of #64 in Medicine/Oncology and #55 in Biochemistry, Genetics, and Molecular Biology, it plays a crucial role in shaping the future of cancer biology. By offering open access to its content, the journal ensures that pivotal research findings are readily available to researchers, professionals, and students globally, thereby fostering collaboration and innovation in cancer research. Situated in Tianjin, China, this journal is poised at the frontier of oncology research, making a significant impact through its rigorous peer-reviewed articles that address critical challenges in the field.

Cancer Gene Therapy, published by SpringerNature, stands at the forefront of research in the fields of cancer research, molecular biology, and molecular medicine. With a robust impact factor reflecting its significant influence—ranking in the Q2 category for cancer research and Q1 for both molecular biology and molecular medicine—it serves as an essential resource for scholars and practitioners alike. Since its inception in 1994, the journal has dedicated itself to advancing the understanding and therapeutic application of genetic innovations in oncology. Notably, it holds distinguished Scopus ranks, placing it among the top tier journals in its categories, underscoring its importance to the scientific community. While open access options are not available, the compelling research published here offers invaluable insights into the latest advancements and strategies in cancer therapy. Engaging with *Cancer Gene Therapy* not only keeps professionals informed but also inspires future innovations in the quest for effective cancer treatments.

MedComm is a distinguished Open Access journal published by Wiley, located in the United States. Since its inception in 2020, it has rapidly established itself as a leading platform for cutting-edge research in the fields of Biochemistry, Cell Biology, Drug Discovery, Genetics, Immunology and Allergy, and Oncology, achieving a prestigious Q1 category ranking across multiple disciplines in 2023. MedComm is committed to providing a rigorous and transparent peer-review process, ensuring the publication of high-quality articles that advance the frontiers of medical science. With its remarkable Scopus ranking, the journal serves as an invaluable resource for researchers, professionals, and students looking to stay abreast of important developments in the life sciences. The open access model facilitates widespread dissemination of scholarly work, fostering collaboration and innovation within the global scientific community. Researchers interested in submitting their work or exploring the latest findings are encouraged to engage with this pivotal journal during the converged years from 2020 to 2024.

Blood Science is a distinguished peer-reviewed journal published by Lippincott Williams & Wilkins, focusing on the dynamic field of hematology. Since its inception, the journal has aimed to disseminate high-quality research and innovative findings that contribute to our understanding of blood-related health issues. With the ISSN 2543-6368, it offers a platform for academic discussions and breakthroughs in various subfields including hematopathology, blood disorders, and transfusion medicine. As of 2023, Blood Science is ranked in the third quartile (Q3) within the hematology category, indicating a burgeoning influence among its peers, with a Scopus rank of #101 out of 137 journals, placing it in the 26th percentile. Although it is not an open-access journal, it provides essential insights and valuable data for researchers, healthcare professionals, and students alike, enhancing the collective knowledge and practices in hematology. With a publication period spanning from 2019 to 2024, Blood Science remains committed to fostering the advancement of blood science research and enhancing patient care methodologies.

Current Research in Translational Medicine, published by ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER, is a dynamic open-access journal that has been at the forefront of innovative research since its inception in 2016. With a strong commitment to advancing the fields of biochemistry, hematology, infectious diseases, oncology, and transplantation, the journal provides an invaluable platform for researchers and practitioners to share novel findings that bridge laboratory discoveries and clinical applications. Currently recognized in prestigious categories such as Q1 and Q2 quartiles, this journal emphasizes the importance of translational science in improving health outcomes, supported by a rigorous editorial process and a commitment to high-quality research dissemination. Being listed in reputable databases like Scopus, it enables authors to reach a wide audience, ensuring that their impactful work contributes to the global dialogue on critical medical advancements. With its open access model, Current Research in Translational Medicine encourages widespread collaboration and engagement among the scientific community, solidifying its role as a leading journal in medicine and related fields.